Clinical characteristics and outcome of surgery in 272 patients with acromegaly who had been treated with a somatostatin receptor ligand before undergoing the surgical procedure
| Variables . | All patients (N = 272) . | Cured (N = 162) . | Not cured (N = 110) . | P value . |
|---|---|---|---|---|
| Age at surgery, years (mean ± SEM) | 47.4 ± 0.8 | 48.8 ± 1.0 | 45.4 ± 1.2 | .03 |
| Estimated duration of disease, years (mean ± SEM) | 7.7 ± 0.3 | 7.9 ± 0.4 | 7.6 ± 0.5 | .70 |
| Male sex, n (%) | 131 (48.2) | 79 (48.8) | 52 (47.3) | .81 |
| Duration of SRL therapy, months (median, IQR) | 11 (6-20) | 11 (6-22) | 12 (6-18) | .71 |
| Basal GH level, µg/L (median, IQR) | 16 (8-32) | 12 (6-21) | 24 (13-45) | <.001 |
| Basal IGF-1, mULN (mean ± SEM)a | 3.15 ± 0.10 | 3.04 ± 0.26 | 3.19 ± 0.11 | .56 |
| Microadenoma, n (%) | 40 (14.7) | 32 (19.8) | 8 (7.3) | .004 |
| Maximum tumor diameter, mm (mean ± SEM)b | 17.9 ± 0.5 | 14.9 ± 0.4 | 22.2 ± 0.9 | <.001 |
| Cavernous sinus invasion, n (%) | 67 (24.6) | 9 (5.6) | 58 (52.7) | <.001 |
| Sphenoid sinus invasion, n (%) | 26 (9.6) | 12 (7.4) | 14 (12.7) | .14 |
| IGF-1 normal during SRL, n (%) | 62 (22.8) | 52 (32.1) | 10 (9.1) | <.001 |
| GH decrease during SRL ≥50%, n (%)c | 178 (69.3) | 108 (71.1) | 70 (66.7) | .45 |
| Tumor reduction during SRL, n (%)d | 78 (52.7) | 45 (54.9) | 33 (50.0) | .56 |
| Variables . | All patients (N = 272) . | Cured (N = 162) . | Not cured (N = 110) . | P value . |
|---|---|---|---|---|
| Age at surgery, years (mean ± SEM) | 47.4 ± 0.8 | 48.8 ± 1.0 | 45.4 ± 1.2 | .03 |
| Estimated duration of disease, years (mean ± SEM) | 7.7 ± 0.3 | 7.9 ± 0.4 | 7.6 ± 0.5 | .70 |
| Male sex, n (%) | 131 (48.2) | 79 (48.8) | 52 (47.3) | .81 |
| Duration of SRL therapy, months (median, IQR) | 11 (6-20) | 11 (6-22) | 12 (6-18) | .71 |
| Basal GH level, µg/L (median, IQR) | 16 (8-32) | 12 (6-21) | 24 (13-45) | <.001 |
| Basal IGF-1, mULN (mean ± SEM)a | 3.15 ± 0.10 | 3.04 ± 0.26 | 3.19 ± 0.11 | .56 |
| Microadenoma, n (%) | 40 (14.7) | 32 (19.8) | 8 (7.3) | .004 |
| Maximum tumor diameter, mm (mean ± SEM)b | 17.9 ± 0.5 | 14.9 ± 0.4 | 22.2 ± 0.9 | <.001 |
| Cavernous sinus invasion, n (%) | 67 (24.6) | 9 (5.6) | 58 (52.7) | <.001 |
| Sphenoid sinus invasion, n (%) | 26 (9.6) | 12 (7.4) | 14 (12.7) | .14 |
| IGF-1 normal during SRL, n (%) | 62 (22.8) | 52 (32.1) | 10 (9.1) | <.001 |
| GH decrease during SRL ≥50%, n (%)c | 178 (69.3) | 108 (71.1) | 70 (66.7) | .45 |
| Tumor reduction during SRL, n (%)d | 78 (52.7) | 45 (54.9) | 33 (50.0) | .56 |
Patients are subdivided according to the surgical outcome.
Abbreviations: GH, growth hormone; IGF-1, insulin-like growth factor 1; IQR, interquartile range; mULN, multiple of the upper limit of the normal; SEM, standard error of the mean; SRL, somatostatin receptor ligand.
aInformation on IGF-1 mULN at diagnosis was available for 184 patients (109 patients in the cured group and 75 in the not cured group).
bInformation on maximum tumor diameter was available for 258 patients (151 in the cured group and 107 in the not cured group).
cPaired data on percent inhibition of GH levels were available in 257 patients (152 in the cured group and 105 in the not cured group).
dPaired data on tumor size reduction were available for 148 patients (82 in the cured group and 66 in the not cured group).
Clinical characteristics and outcome of surgery in 272 patients with acromegaly who had been treated with a somatostatin receptor ligand before undergoing the surgical procedure
| Variables . | All patients (N = 272) . | Cured (N = 162) . | Not cured (N = 110) . | P value . |
|---|---|---|---|---|
| Age at surgery, years (mean ± SEM) | 47.4 ± 0.8 | 48.8 ± 1.0 | 45.4 ± 1.2 | .03 |
| Estimated duration of disease, years (mean ± SEM) | 7.7 ± 0.3 | 7.9 ± 0.4 | 7.6 ± 0.5 | .70 |
| Male sex, n (%) | 131 (48.2) | 79 (48.8) | 52 (47.3) | .81 |
| Duration of SRL therapy, months (median, IQR) | 11 (6-20) | 11 (6-22) | 12 (6-18) | .71 |
| Basal GH level, µg/L (median, IQR) | 16 (8-32) | 12 (6-21) | 24 (13-45) | <.001 |
| Basal IGF-1, mULN (mean ± SEM)a | 3.15 ± 0.10 | 3.04 ± 0.26 | 3.19 ± 0.11 | .56 |
| Microadenoma, n (%) | 40 (14.7) | 32 (19.8) | 8 (7.3) | .004 |
| Maximum tumor diameter, mm (mean ± SEM)b | 17.9 ± 0.5 | 14.9 ± 0.4 | 22.2 ± 0.9 | <.001 |
| Cavernous sinus invasion, n (%) | 67 (24.6) | 9 (5.6) | 58 (52.7) | <.001 |
| Sphenoid sinus invasion, n (%) | 26 (9.6) | 12 (7.4) | 14 (12.7) | .14 |
| IGF-1 normal during SRL, n (%) | 62 (22.8) | 52 (32.1) | 10 (9.1) | <.001 |
| GH decrease during SRL ≥50%, n (%)c | 178 (69.3) | 108 (71.1) | 70 (66.7) | .45 |
| Tumor reduction during SRL, n (%)d | 78 (52.7) | 45 (54.9) | 33 (50.0) | .56 |
| Variables . | All patients (N = 272) . | Cured (N = 162) . | Not cured (N = 110) . | P value . |
|---|---|---|---|---|
| Age at surgery, years (mean ± SEM) | 47.4 ± 0.8 | 48.8 ± 1.0 | 45.4 ± 1.2 | .03 |
| Estimated duration of disease, years (mean ± SEM) | 7.7 ± 0.3 | 7.9 ± 0.4 | 7.6 ± 0.5 | .70 |
| Male sex, n (%) | 131 (48.2) | 79 (48.8) | 52 (47.3) | .81 |
| Duration of SRL therapy, months (median, IQR) | 11 (6-20) | 11 (6-22) | 12 (6-18) | .71 |
| Basal GH level, µg/L (median, IQR) | 16 (8-32) | 12 (6-21) | 24 (13-45) | <.001 |
| Basal IGF-1, mULN (mean ± SEM)a | 3.15 ± 0.10 | 3.04 ± 0.26 | 3.19 ± 0.11 | .56 |
| Microadenoma, n (%) | 40 (14.7) | 32 (19.8) | 8 (7.3) | .004 |
| Maximum tumor diameter, mm (mean ± SEM)b | 17.9 ± 0.5 | 14.9 ± 0.4 | 22.2 ± 0.9 | <.001 |
| Cavernous sinus invasion, n (%) | 67 (24.6) | 9 (5.6) | 58 (52.7) | <.001 |
| Sphenoid sinus invasion, n (%) | 26 (9.6) | 12 (7.4) | 14 (12.7) | .14 |
| IGF-1 normal during SRL, n (%) | 62 (22.8) | 52 (32.1) | 10 (9.1) | <.001 |
| GH decrease during SRL ≥50%, n (%)c | 178 (69.3) | 108 (71.1) | 70 (66.7) | .45 |
| Tumor reduction during SRL, n (%)d | 78 (52.7) | 45 (54.9) | 33 (50.0) | .56 |
Patients are subdivided according to the surgical outcome.
Abbreviations: GH, growth hormone; IGF-1, insulin-like growth factor 1; IQR, interquartile range; mULN, multiple of the upper limit of the normal; SEM, standard error of the mean; SRL, somatostatin receptor ligand.
aInformation on IGF-1 mULN at diagnosis was available for 184 patients (109 patients in the cured group and 75 in the not cured group).
bInformation on maximum tumor diameter was available for 258 patients (151 in the cured group and 107 in the not cured group).
cPaired data on percent inhibition of GH levels were available in 257 patients (152 in the cured group and 105 in the not cured group).
dPaired data on tumor size reduction were available for 148 patients (82 in the cured group and 66 in the not cured group).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
